Fischer Medical Ventures Limited, a prominent company focused on developing innovative and cost-effective solutions in medical imaging, advanced diagnostics, and point-of-care diagnostics, has released its unaudited consolidated financial results for the second quarter (Q2) and first half (H1) of Fiscal Year 2026.
The results showcase a strong operational period, marked by significant growth across key financial parameters. Fischer Medical Ventures Limited was formerly known as Fischer Chemic Limited.
Fischer Medical Ventures reported a substantial year-over-year (YoY) surge in total income for Q2 FY26.
The company reported a strong year-on-year performance in Q2 FY26. Total income rose to ₹88.79 crore from ₹39.88 crore in Q2 FY25, marking a growth of 122.64%. EBITDA stood at ₹18.74 crore compared to ₹0.72 crore in the same quarter last year, reflecting a 2,511.72% increase. The EBITDA margin expanded sharply to 21.10% from 1.80%, showing an improvement of 1,930 basis points.
Net profit surged to ₹13.96 crore from ₹0.29 crore in Q2 FY25, a rise of 4,659.63%. The net profit margin improved to 15.72% from 0.74%, up by 1,499 basis points. Earnings per share (EPS) also increased significantly to ₹2.11 from ₹0.05, recording a growth of 4,200%.
For the first half of FY26 (H1 FY26), the company also posted strong increases: Total Income reached ₹ 119.70 Cr, marking a 135.90% increase from ₹ 50.74 Cr in H1 FY25. EBITDA for H1 FY26 stood at ₹ 30.46 Cr, surging 2,274.35% from ₹ 1.28 Cr in H1 FY25. Net Profit saw a dramatic increase of 10,664.64% YoY, rising to ₹ 18.97 Cr in H1 FY26 from ₹ 0.18 Cr in H1 FY25.
Commenting on the Results, Mr. Ravindran Govindan, Chairman of Fischer Medical Ventures Limited, said: “Q2 was a very strong quarter for Fischer, marking significant improvement across all operational and financial parameters. The steep rise in profitability reflects the scalability of our model, better product realization, and the growing acceptance of Fischer’s technology across India and overseas markets.
India’s MedTech and diagnostic industry is expanding rapidly, driven by government focus on indigenous manufacturing, preventive care, and AI-led healthcare solutions. Fischer is well aligned with these trends, leveraging its expertise in MRI systems, AI diagnostics, and digital health platforms to strengthen its position in this evolving landscape.
With our expanding footprint across Southeast Asia, new product launches, and advanced solutions such as SpinCare® and portable X-ray systems, we are confident of sustaining this growth momentum and creating long-term value for all”
Global Expansion and Partnerships
Fischer Medical Ventures continued its global strategic expansion during the quarter:
Diagnostic Imaging Expansion in India
FMV expanded its diagnostic imaging presence within India by launching a High-Resolution Open MRI at Sunray Scans in Chennai and installing the PICA 0.35T Open MRI at STNM Hospital in Sikkim. The subsidiary, Fischer Medical Ventures Limited (FMVL), is the first Indian company recognized by CDSCO for the indigenous manufacturing of MRI systems.
AI Innovation Recognition
NYB.AI, a Joint Venture Partner of FMV, won the 1st Prize at the SuperAI Genesis Global Competition. This recognition was given for their AI-driven drug discovery platform, DTIGN. NYB.AI’s partners include prominent names such as NVIDIA, J&J Innovation, and HPE.
Nanomedic and SpinCare® Progress
On Thursday, Fischer Medical Ventures share price jumped over 3% to hit an intraday high of ₹120 per share. As of 10:57 am IST, the stock price was trading at ₹117.86 per share, up by 2.18%. The company got listed on exchanges on July 10, and since then, the stock price has given returns of 41.53%.
For android only